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Abstract
Background: Longlasting and unbearable pain is the most common and striking symptom of chronic
pancreatitis. Accordingly, pain relief and improvement in patients' quality of life are the primary goals in
the treatment of this disease. This systematic review aims to summarize the available data on treatment
options.
Methods: A systematic search of MEDLINE/PubMed and the Cochrane Library was performed accord-
ing to the PRISMA statement for reporting systematic reviews and meta-analysis. The search was limited
to randomized controlled trials and meta-analyses. Reference lists were then hand-searched for addi-
tional relevant titles. The results obtained were examined individually by two independent investigators for
further selection and data extraction.
Results: A total of 416 abstracts were reviewed, of which 367 were excluded because they were
obviously irrelevant or represented overlapping studies. Consequently, 49 full-text articles were system-
atically reviewed.
Conclusions: First-line medical options include the provision of pain medication, adjunctive agents and
pancreatic enzymes, and abstinence from alcohol and tobacco. If medical treatment fails, endoscopic
treatment offers pain relief in the majority of patients in the short term. However, current data suggest that
surgical treatment seems to be superior to endoscopic intervention because it is significantly more
effective and, especially, lasts longer.
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Introduction
Chronic pancreatitis (CP) is a painful inflammatory disease that
leads to progressive and irreversible destruction of the pancreatic
parenchyma.1,2 Recurrent episodes of acute pancreatitis may result
in tissue fibrosis and the loss of exocrine and endocrine function,
along with steatorrhea, malabsorption, diabetes and unbearable
pain.3 The majority of patients with CP demonstrate constant
or recurrent severe and often opioid-refractory abdominal pain.
Pancreatic pain characteristically presents as deeply penetrating
and dull epigastric pain, which radiates to the back and is often
worsened by ingestion. This classical pattern of pain is not uni-
versal, and the character, location and quality of pain can be quite
inconsistent.4
A pathophysiological mechanism for pain in CP that has been
repeatedly discussed is the increase in intrapancreatic pressure
either within the pancreatic duct or in the pancreatic parenchyma,
which leads to ischaemia and the inflammation of pancreatic
tissue.5,6 It is noteworthy in this context, however, that there seems
to be no direct relationship between the presence of duct dilata-
tion and pain.7 Furthermore, it has long been recognized that the
severity of abdominal pain sensations correlates with the extent of
intrapancreatic neural damage and alterations.8,9 However, the
underlying molecular pathways are incompletely understood and
probably multifactorial. A hypothesis that is increasingly dis-
cussed proposes that neural inflammatory cell infiltration leads to
pancreatic neuritis and neural plasticity with enlarged nerves and
the formation of a dense intrapancreatic neural network. All these
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neural alterations are responsible for causing the characteristic
pancreatic neuropathy and consequent neuropathic pain.8–12
Because the underlying pain mechanisms are just beginning to be
understood, the treatment of pain in CP is often empirical and
insufficient. The objective of this article was to review, summarize
and assess the level of evidence on the effectiveness of different
treatment options in painful CP.
Materials and methods
Searches of the MEDLINE, PubMed and Cochrane Library data-
bases were performed using the search terms ‘pain’, ‘treatment’,
‘analgesia’, ‘surgery’ and ‘endoscopy’ and, alternatively, these terms
matched with ‘chronic pancreatitis’ for papers published from the
inception of the database in question to 31 March 2013. Searches
were limited to English-language articles describing randomized
controlled trials (RCTs) and meta-analyses as these are considered
to represent the highest level of evidence.
The results obtained were examined individually by two inde-
pendent investigators (JGD’H, GOC). Firstly, titles and abstracts
were read; if the article was considered relevant by at least one of
the investigators, full-text articles were retrieved and studied.Arti-
cles for inclusion were required to report on studies that had
systematically investigated any form of treatment in patients with
painful CP and used pain reduction as one of their outcome
measures. Articles reporting on studies outwith the scope of the
review and those that overlapped across the searches were
excluded. Reference lists extracted from the 49 full-text articles
published between 1983 and 2012 and selected for systematic
review were hand-searched for additional relevant titles.
The following study characteristics were extracted from the
articles: authors; publication year; publishing journal; study
design and size; study duration; type of intervention, and outcome
measures related to pain. Studies were categorized according to
the primarily investigated treatment strategy for painful CP based
on whether they referred to medical treatment, interventional
treatment (including endoscopic and radiological interventions),
surgical treatment, and any comparisons between any of these
types of treatment.
Results
The initial search identified 416 articles. Duplicate studies were
excluded (n = 88). Screening of titles and abstracts resulted in the
exclusion of a further 279 articles, the content of which fell
outwith the scope of this review and was obviously irrelevant
(Fig. 1). Finally, 49 studies were included for full-text review.
Medical treatment
The initial challenge in CP concerns making the correct diagnosis.
Early-stage CP has been recognized in the context of endoscopic
ultrasound (EUS) when patients present with typical pancreatic-
type pain. However, whether these EUS findings represent true
early-stage CP that will progress or whether they are false positive
findings remains unclear.13 Diagnosis can be especially challeng-
ing in small duct disease because patients often lack characteristic
structural changes. Accordingly, patients with small duct CP are
generally poorly represented in all of the published studies on
treatment of painful CP. Once the diagnosis of CP is confirmed,
patients are advised to maintain a strict abstinence from tobacco
‘Pain’: 2660 studies ‘Treatment’: 7968 studies ‘Analgesia’: 72 studies
‘Pain’: 83 studies
Only English-language articles, RCTs and meta-analysis
‘Treatment’: 176 studies ‘Analgesia’: 6 studies
‘Surgery’: 7358 studies
‘Surgery’: 120 studies
‘Endoscopy’: 2380 studies
‘Endoscopy’: 31 studies
Total: 416 studies
416 abstracts reviewed 367 excluded:
-  279 obvious irrelevance
-  88 studies overlapped
49 full-text articles reviewed
Figure 1 Flow diagram showing the present literature review, determination of eligibility and inclusion of studies in the systematic review.
RCT, randomized controlled trial
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and alcohol and require longterm analgesic medications for pain
control. For pain medication titration, the step-up approach of
the analgesic ladder described by the World Health Organization
(WHO) is proposed (Fig. 2). Tramadol is one of the few analgesic
medications to have been prospectively evaluated in painful CP
and has been shown to be equivalent to more potent narcotics,
with a lower incidence of gastrointestinal side-effects and less
potential for addiction.14 Transdermal fentanyl plaster may be
useful in some patients, but it is not the ideal first-choice analgesic
because it implies a considerable need for additional rescue mor-
phine and skin-related side-effects.15 Allopurinol has been shown
to be ineffective in a very small randomized trial.16 Although
evidence is low for CP pain, the additional treatment of these pain
states with non-narcotic adjunctive medications such as selective
serotonin reuptake inhibitors (SSRIs) has become increasingly
popular as these agents have been successfully used in other
chronic pain states.17,18 Because pancreatic pain syndrome has
been identified as neuropathic,8 novel approaches for pain treat-
ment have been tested. Here, the gabapentoid pregabalin has been
identified as a successful therapeutic tool in adjunctive medication
for the treatment of pancreatic pain in patients with CP.19–22
Pancreatic enzyme supplementation is frequently used in
patients with painful CP although, despite several prospective
trials andmeta-analysis, evidence for pain reduction through pan-
creatic enzyme replacement remains inconsistent.23–29 However, as
pancreatic enzyme supplementation usually has positive effects on
diarrhoea, fat malabsorption and weight loss with no relevant
side-effects, a therapeutic regime with a pancreatic enzyme sup-
plement is generally appropriate for 6–8 weeks and should be
discontinued if it proves ineffective.30,31 In such instances, non-
enteric coated enzymes should always be prescribed, together with
a proton-pump inhibitor to prevent the hydrolysis of the enzyme
by gastric acid.32
Other medical therapies, such as antioxidants or octreotide,
used in the treatment of CP have been repeatedly studied and
discussed, but the results of these investigations remain inconclu-
sive and therefore the use of these therapies is not recommended
in daily routine.33–39 This is underlined by the results of the most
recent RCT on the use of antioxidants (the ANTICIPATE Study)
which did not show any effect on pain in patients with CP.40
Researchers evaluating these placebo-controlled studies should
keep in mind the finding that the pooled estimated placebo rate of
abdominal pain remission in clinical trials of CP has been shown
to be almost 20%, which can make interpretation of results quite
difficult.41
Acupuncture and transcutaneous electric nerve stimulation
were evaluated during the mid-1980s, but neither proved to show
any substantial pain relief that could substitute for or supplement
medical treatment.42
Interventional treatment
Coeliac block
If sufficient pain relief cannot be achieved by medical therapy, and
if there is no sign of pancreatic or biliary duct obstruction, more
invasive strategies should be considered. As most pancreatic
nociceptive afferents are thought to pass through the coeliac gan-
glion, nerve block (anaesthetic and/or steroid) or neurolysis
(alcohol) represent common treatment options for pancreatic
pain.About half of patients treated with EUS-guided coeliac block
for painful CP experience a significant decrease in pain.43 Here,
EUS-guided techniques have proven safer,more effective andmore
longlasting than fluoroscopy-guided or computed tomography
(CT)-guided techniques.43–45 The addition of triamcinolone to
standard bupivacaine for the EUS-guided block does not increase
pain relief or lengthen the effects and it makes no difference
whether one or two injections are applied.46,47 A single old and
underpowered randomized study comparing the effects of coeliac
plexus block with a surgical procedure (pancreaticogastrostomy)
suggests the operative procedureprovides better longtermresults.48
Unfortunately, in most cases coeliac nerve block shows only a
transient effect and persistent pain relief is maintained in only
about 10% of patients at 24 weeks.49 Therefore, this therapeutic
option seems to be more effective and reasonable in patients with
malignant disease and a short anticipated lifespan.However,neural
block strategies to achieve temporary pain relief may be considered
in patients with CP and severe pain.50
Thoracoscopic splanchnicectomy
A more invasive procedure that is similar to the percutaneous
or endoscopic coeliac plexus block is bilateral thoracoscopic
splanchnicectomy. This can be performed with a higher degree of
precision and avoids the side-effects associated with the local
diffusion of neurolytic solutions.51 However, similarly to the
coeliac plexus block, most studies show that thoracoscopic
splanchnicectomy seems to be more effective in the short term
because early good results decline with time after the interven-
tion.52 Given the contradictory results reported in the literature,
Step 3: Opioid for 
moderate to severe 
pain
+/- Non-opioid
+/- Adjuvant
Step 2: Opioid for 
mild to moderate 
pain
+/- Non-opioid
+/- AdjuvantStep 1: Non-opioid
+/- Adjuvant
PAIN
Figure 2 The analgesic ladder defined by the World Health Organi-
zation. Adapted from the World Health Organization101
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thoracoscopic splanchnicectomy cannot be recommended as
a standard treatment option to achieve the longterm relief of pain
in CP.
Endoscopy
Endoscopic therapy aims to relieve pain by draining the main
pancreatic or biliary duct to reduce the pressure of the pancreatic
parenchyma. It may be used for the treatment of local complica-
tions, such as ductal strictures, stones or pancreatic pseudocysts,
in appropriately pre-selected patients. Nearly half of patients
referred for non-surgical pancreatic duct drainage procedures
require the extraction of obstructing stones. This is traditionally
attempted by endoscopic retrograde cholangiopancreatography
(ERCP) after pancreatic sphincterotomy if the stones are <10 mm
in diameter, not too numerous and located in the main duct.53
Unfortunately, many patients do not meet these criteria and are
therefore not suitable for endoscopic treatment. However, large,
retrospective, non-randomized multicentre series have demon-
strated that in a very select group of patients with ductal anatomy
that is amenable to endoscopic therapy, significant pain relief can
be achieved (with a median of three ERCPs) in approximately
two-thirds of all treated patients.54,55 A randomized trial compar-
ing the outcomes of endoscopic stenting with those of a sham
procedure for painful CP, in which the improvement of abdomi-
nal pain is the primary endpoint, is currently recruiting.56
Extracorporeal shock wave lithotripsy
In addition to endoscopic therapy, extracorporeal shock wave
lithotripsy (ESWL) is a safe method of fragmenting stones prior to
ERCP and should therefore be considered to decrease the number
of ERCPs needed for successful stone clearance.57 Furthermore,
increasing evidence demonstrates that ESWL alone may be an
effective solitary option in patients with painful CP and pancreatic
duct dilatation.58–60
Surgical treatment
Classical indications for surgery in CP are stenosis of the common
bile duct or the duodenum, vascular obstruction, pseudocysts, the
suspicion of neoplasm, and abdominal pain that fails to respond
to conservative and endoscopic treatment options. The main
purpose of a surgical intervention in CP is the relief of pain and
the simultaneous preservation of as much of the pancreatic paren-
chyma as possible. Very few studies have examined the optimal
timing of surgical therapy, but the resulting data indicate that
early intervention would seem to be more beneficial. A study
published by Nealon and Thompson suggested that early opera-
tive duct decompression should be performed in patients with CP
because it can delay the progressive functional destruction of the
pancreas.61 Ihse et al. drew similar conclusions in patients with
dilatation or obstruction of the pancreatic duct and biliary pan-
creatitis,62 whereas others have described a progressive functional
impairment despite surgery.63 The latest study identified surgery
within 3 years of the onset of symptoms, fewer than five previous
endoscopic treatments, and the absence of preoperative opioid use
as independent factors associated with the achievement of greater
pain relief.64 Similar results were shown recently by van der Gaag
et al., who were able to show that preoperative daily opioid use
and high numbers of preceding endoscopic procedures are asso-
ciated with persistent severe pain.65 Furthermore, these authors
showed that both physical and mental quality of life (QoL)
remained postoperatively impaired in comparison with QoL in
the general population.65 However, it is apparent across the studies
that the lack of any commonly accepted system for staging CP
makes comparisons very difficult. Therefore, current data are still
insufficient to allow for final recommendations, but suggest that
an early surgical intervention within the first 3 years of the onset
of symptoms may be beneficial.66
The first surgical attempts to relieve pancreatic pain in CP were
initiated in the early 19th century and were focused on the drain-
ing of the pancreatic duct by means of pancreatostomy67 or pan-
creatic left resection.68 Since then, surgical strategies for the
treatment of CP have continuously evolved. Puestow and Gillesby
were the first to combine a pancreatic left resection with a longi-
tudinal opening of the pancreatic duct and an anastomosis to the
small intestine.69 Only 2 years later, Partington and Rochelle pub-
lished what they called a ‘modified’ Puestrow–Gillesby procedure,
in which they preserved the tail of the pancreas and extended the
opening of the pancreatic duct.70 This surgical technique is nowa-
days known as the Partington–Rochelle procedure and continues
to be used in surgical practice, with low morbidity and mortality,
especially in patients with dilated pancreatic ducts of >7 mm. This
drainage operation has been shown to facilitate longterm pain
relief in around 60–70% of patients, although some groups have
reported even higher success rates of up to 98% in selected
patients.71,72
Drainage operations are usually ineffective in patients without
dilatation of the main pancreatic duct. These patients’ pain sen-
sations are thought to evolve from neuropathic changes within the
pancreatic head, as described earlier. Long before these underlying
neural alterations are discovered, the pancreatic head is identified
as the leading site of the disease, often carrying a dominant
inflammatory mass.73 Therefore, several surgical procedures have
been applied for the resection of the pancreatic head. The stand-
ard Kausch–Whipple procedure for the radical resection of the
pancreatic head, duodenum and gastric antrum with the pylorus
and gallbladder was initially established in the early 19th century
for the treatment of malignancies of the pancreatic head and the
periampullary region, but has subsequently also been used in the
resection of inflammatory pancreatic head masses. As a result of
relatively high rates of gastrointestinal symptoms and diabetes
mellitus, the classic Kausch–Whipple procedure has often been
replaced by the pylorus-preserving Whipple procedure intro-
duced by Traverso and Longmire in 1978.74,75 This Traverso–
Longmire procedure has proven to lead to longterm pain relief in
around 90% of patients with painful CP.75,76 In the long term,
however, the pylorus-preserving procedure has not been shown to
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offer any clear advantages in terms of gastrointestinal symptoms
and diabetes mellitus.77 Therefore, pancreaticoduodenectomy
either with or without pylorus preservation may be considered in
patients with painful CP. In severe cases of CP in which the entire
gland is affected, even total pancreatectomy is a viable option, in
which perioperative morbidity andmortality are comparable with
those of the Traverso–Longmire procedure and the resultant
overall QoL is acceptable.78 However, based on the rationale that a
resection of the gastric antrum, duodenum and common bile duct
in benign disease may represent an overtreatment, Hans-Günther
Beger introduced the duodenum-preserving resection of the pan-
creatic head in 1972.73 In the Beger procedure, the neck of the
pancreas is divided over the portal vein, and the head and uncinate
process of the pancreas are carefully excised, sparing the duo-
denum and the intrapancreatic bile duct. Fifteen years later, Frey
and colleagues described a variation of the Beger procedure
involving a more limited and organ-preserving resection in which
the pancreatic head is decorticated and the duct is widely opened.
Drainage is then achieved by pancreaticojejunostomy.79 The Frey
procedure is commonly regarded as technically easier than the
Beger operation because it does not require the dissection of the
pancreas above the portal vein and the reconstruction is less
complex. The Beger procedure was later modified by Markus W.
Büchler to only partial resection of the pancreatic head and a
short-range lateral pancreaticojejunostomy, known as the Berne
technique.80,81 In 1998, Izbicki et al. introduced another
parenchyma-preserving procedure in which a longitudinal
V-shaped excision of the anterior pancreas is performed; nowa-
days this is not commonly performed, but it remains a treatment
option, particularly in patients with small duct CP.82 Finally,
Müller and colleagues have described a middle segmental pancre-
atic resection for use in patients with focal CP using a linear cutter
and a retrocolic Roux-en-Y limb of jejunum for reconstruction, in
which morbidity and mortality rates are comparable with those of
other pancreatic resection procedures.83 One study suggests that
perioperative octreotide may reduce the risk for postoperative
complications in patients undergoing major pancreatic surgery
for CP.84
When it comes to the issue of which of these procedures
represents the optimal choice, evidence is limited to some
monocentre trials and two meta-analyses (Table 1). In the first
RCT on the type of surgical treatment for painful CP, Klempa and
colleagues compared the classic Whipple procedure (n = 21) with
the Beger procedure (n = 22). Here, patients submitted to a Beger
procedure experienced less pain, better gain in body weight, better
endocrine function and a shorter hospital stay.85 A similar study
was published in 1995 by Büchler et al., who compared the
duodenum-preserving pancreatic head resection (n = 20) with the
pylorus-preserving Whipple procedure (n = 20). Again, the
duodenum-sparing resection provided a better outcome in terms
of pain relief, weight gain, glucose tolerance and insulin secretion
capacity.80 However, these convincing early advantages of the
Beger procedure were not maintained during the longterm
follow-up of these patients (up to 14 years).86 Two randomized
trials have compared the pylorus-preserving Whipple procedure
with the Frey procedure; both showed the two procedures to be
equally efficient in terms of providing pain relief. However, they
also showed that the Frey procedure results in better QoL,
although postoperative endocrine and exocrine pancreatic func-
tion were equivalent.82,87,88 Strate et al. compared the Beger pro-
cedure (n = 38) with the Frey procedure (n = 36) and were unable
to show any difference between those two surgical options in
mortality, QoL, pain relief, or exocrine and endocrine function.89
These data underline previous findings by Izbicki and colleagues
in a slightly smaller cohort.90 Köninger et al. state that the Büchler
procedure can be performed significantly faster and leads to a
shorter hospital stay than the Beger operation.91 Finally, the most
recent randomized trial was published in 2012 by Keck and
Table 1 Randomized controlled trials comparing surgical techniques in the treatment of painful chronic pancreatitis
Techniques compared Authors Patients, n Outcome
Classic Whipple versus Beger Klempa et al.85 43 Beger procedure: less pain, greater weight gain, shorter
hospital stay
Pylorus-preserving Whipple
versus Beger
Büchler et al.80 40 Beger procedure: less pain, greater weight gain, better glucose
tolerance, higher insulin secretion capacity
Pylorus-preserving Whipple
versus Frey
Izbicki et al.82 61 Equally effective in terms of pain relief and definitive control of
complications; Frey procedure provides better quality of life
Pylorus-preserving Whipple
versus modification of Frey
Farkas et al.87 40 Equally effective in pain relief; Frey procedure is superior in
morbidity, hospital stay, and weight gain
Beger versus Frey Strate et al.89 74 Both procedures provide adequate pain relief and quality of life
after longterm follow-up with no differences regarding
exocrine and endocrine function
Beger versus Büchler Köninger et al.91 65 No differences in quality of life, significantly shorter operation
times and hospital stay for the Büchler procedure
Pylorus-preserving Whipple versus
duodenum-preserving pancreatic
head resection (Beger or Frey or
Büchler)
Diener et al.93 Recruiting
Aim = 200
Expected 2013
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colleagues, who found no difference between duodenum preser-
vation and resection and suggested that both techniques are
equally effective in the short and long term.92 The recently pub-
lished protocol for the ChroPac Trial pertains to the first large,
multicentre RCT to compare duodenum-preserving pancreatic
head resection with pancreatoduodenectomy with the primary
outcome represented by the patient’s QoL at 24 months after
surgery.93 The first results of this trial are expected in late 2013.
Although 24 months may not represent a sufficiently long period
for the estimation of longterm results, it is hoped that the trial will
provide a better idea of the short-term outcomes and morbidity
rates associated with these procedures. Until then, surgeons will be
required to rely on the data currently available from these small
trials. The existing data are best summarized in a recently pub-
lished meta-analysis, in which duodenum-preserving pancreatic
head resections (including those of the Beger, Frey and Büchler
procedures) and pancreatoduodenectomy were shown to be
equally effective in terms of pain relief, overall morbidity and
incidence of postoperative endocrine insufficiency.94 However, the
duodenum-preserving pancreatic head resection seems to be
superior in terms of postoperative weight gain, exocrine and
endocrine function, and longterm QoL. Similar results were
obtained for the Beger and Frey procedures;94 however, the most
recent meta-analysis suggests that the Beger procedure provides
for better pain relief but higher morbidity, and the Frey procedure
provides less sufficient pain relief but lower morbidity.95 There-
fore, any of these surgical techniques are appropriate for the sur-
gical treatment of painful CP. However, with reference to
postoperative functional outcome, it should be remembered that
most of these series show a postoperative deterioration in pancre-
atic function to some extent, which is probably unavoidable when
pancreatic tissue is operatively removed. Furthermore, any inter-
pretation of the longterm results of these studies should be made
in the awareness that pancreatic pain may reduce spontaneously
over time in line with the concept of ‘burnout’ outlined by Rudi
Ammann et al. several years ago.96
A fairly new surgical technique that has been developed recently
is that of autologous islet transplantation after total pancreatec-
tomy. The most recent systematic review showed that a significant
proportion of patients remained independent of need for insulin
supplementation even in the long term (ranging from 46% at 5
years to 10% at 8 years).97 Although it may be too early to consider
this option as a standard procedure, it may become a valid option
in patients in whom total pancreatectomy is unavoidable.
Comparative studies
Endoscopic and surgical interventions are subject to controversy
but both can be considered in CP patients in whom conservative
pain treatment fails. Two RCTs have addressed the obvious ques-
tion of whether endoscopic or surgical treatment is superior in the
initial treatment of CP. Dite and colleagues were the first to inves-
tigate this controversial issue in an RCT.98 A total of 72 patients
were randomized to either endoscopy or surgery, in which resec-
tion was the most common surgical procedure (80%) and surgical
drainage was performed in 20% of patients. The most commonly
performed endoscopic interventions were sphincterotomy and
stenting, performed in 52% of patients, and/or stone removal,
performed in 23% of patients in the endoscopy arm. Initial
success rates in terms of pain relief were similarly high (>90% of
patients achieved at least partial pain relief at 1 year) in both
groups, but these clinical outcomes changed considerably at 3
years and 5 years of follow-up. In the surgical treatment group,
42% of patients were found to have maintained complete pain
relief at 1 year, which marginally decreased to 41% at 3 years and
37% at 5 years. By contrast, patients in the endoscopic treatment
arm initially showed an equally good clinical outcome, with 52%
of patients enjoying complete pain relief at 1 year, but this effect
substantially decreased to 11% at 3 years and 14% at 5 years.
Accordingly, the rate of non-responders was disappointingly high
at 33–35% in the endoscopy arm versus only 12–14% in the
surgical treatment arm after 3 years and 5 years. Furthermore,
similar outcomes in patient body weight became apparent. Ini-
tially, at 1 year after treatment, 60% of patients in the surgery
treatment arm and 66% in the endoscopy arm achieved an
increase in body weight, but this clinical outcome was found to
have changed significantly at 5 years of follow-up. Only 27% of
patients in the endoscopic treatment group showed a gain in body
weight at 5 years, whereas >50% of patients in the surgical treat-
ment group demonstrated a gain in body weight. In this RCT,Dite
et al. were able to show for the first time that surgery seems to be
superior to endoscopic treatment in terms of the achievement of
longterm pain relief and gain in body weight.98
In 2007 Cahen and colleagues published a report on the second
and more recent study on the same issue,99 and provided a very
recent update of longterm follow-up in August 2011.100 Here, 39
patients were randomized to endoscopy (n = 19) or operative
pancreaticojejunostomy (n = 20). Following an unscheduled
interim analysis after a median follow-up of 24 months, the study
was terminated early because of highly significant mean differ-
ences in the Izbicki pain score (11 versus 34) in favour of the
surgical treatment arm (P < 0.001). Even more striking were the
immense differences in the frequency of patients achieving com-
plete or partial pain relief at the end of follow-up, with only 32%
of patients in the endoscopic treatment group but 75% in the
surgical treatment group showing at least partial relief. Further-
more, at longterm follow-up of up to 7 years, these numbers
had not changed considerably (38% versus 80%). Additionally,
endoscopically treated patients underwent significantly more
re-interventions than surgically treated patients (n = 8 versus n =
3). There were no significant differences between the treatment
groups in the number of complications. Although the endoscopy
group experienced more overall complications than the surgery
group (11 of 19 patients, 58%), all of these were minor. By con-
trast, only seven of 20 patients (35%) in the surgery group dem-
onstrated complications. However, the only major complication
to occur in the course of the trial developed in the surgery group.
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In addition, there were no differences between the treatment
groups in the length of hospital stay or the number of hospital
readmissions.100 On the basis of these results, the authors con-
cluded that surgical drainage is superior to endoscopic treatment
and should be regarded as the preferred treatment option.100
However, in less extensive disease, the authors still consider endo-
scopic treatment as a valuable alternative to surgery.100
Given the conclusions of these two RCTs, it would seem to be
evident that surgical therapy is more effective and longer-lasting
than endoscopic treatment and that rates of morbidity and mor-
tality are comparable in both. Although these trials may be too
small to enable the detection of possible differences in these sec-
ondary outcome measures, and larger RCTs may be required to
confirm current evidence, surgical treatment for pain in CP must
be regarded as the current standard of care. However, it should be
noted that a subgroup of patients representing about 30% of the
study population in both studies do seem to profit, even in the
long term, from endoscopic treatment alone. A primary endo-
scopic approach may therefore also be justified in mild disease.
Future studies should focus on further defining that group of
patients who may benefit from a less invasive procedure.
Conclusions
Two of the primary goals in treating CP remain the provision of
longterm pain relief and the facilitating of improvement in the
patient’s QoL. Achieving these goals remains an interdisciplinary
challenge for radiologists, pain medicine specialists, gastroenter-
ologists and surgeons. If pain relief and a consequent improve-
ment in the patient’s QoL cannot be achieved by medical therapy,
current evidence suggests that surgery is the treatment of choice
and is superior to endoscopic treatment. An initial endoscopic
trial may be warranted, but, in the event of its failure, early sur-
gical management is advised. Pancreatic resections can nowadays
be performed with low morbidity and mortality in high-volume
centres and can provide longterm pain relief in the vast majority
of patients with painful CP. However, current evidence is largely
based on the findings of small underpowered studies that dem-
onstrate considerable risk for bias. Therefore, although they will
be challenging to set up, larger RCTs with sufficient power are
needed to confirm current evidence.
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